Journals / Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi / 2026 / Volume: 46 Issue: 3

Analytical Method Development and Validation for Nirogacestat Using UV Spectrophotometry

P Ravisankar(Vignan Pharmacy College (A))0000-0003-4450-5732
Jasvitha Mandava(Vignan Institute of Pharmaceutical Technology(A))0009-0009-8945-3316
Vasudha Dadı(Vignan Institute of Pharmaceutical Technology)0000-0003-3862-0590
Pages
—
Publication Date
2026-09-01
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

It is eminently suitable for routine quality assessment and quantitative evaluation of Nirogacestat in bulk drug substances and tablet formulations.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:The primary aim of the current investigation was the Analytical progression and validation of a UV-spectrophotometric analytical approach for the quantification of Nirogacestat in both bulk and pharmaceutical dosage forms, in alignment with ICH regulatory standards.
📊
Key Findings & Data:The absorbance of the analyte solution was recorded at 269 nm relative to a suitable blank.
💡
Conclusion & Impact:It is eminently suitable for routine quality assessment and quantitative evaluation of Nirogacestat in bulk drug substances and tablet formulations.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Ultraviolet Spectroscopy · Validation · Nirogacestat

Abstract

The primary aim of the current investigation was the Analytical progression and validation of a UV-spectrophotometric analytical approach for the quantification of Nirogacestat in both bulk and pharmaceutical dosage forms, in alignment with ICH regulatory standards. A straightforward, expeditious, reliable, and economically viable UV-spectrophotometric technique was established for the quantitative determination of Nirogacestat employing acetonitrile as the solvent medium. The absorbance of the analyte solution was recorded at 269 nm relative to a suitable blank. Method validation was performed pursuant with prescribed parameters, encompassing linearity, accuracy, precision and robustness. The λmax of Nirogacestat in acetonitrile was identified at 269 nm. The analyte demonstrated compliance with Beer-Lambert’s law across the concentration interval of 2.5–15.0 μg/mL, exhibiting a correlation coefficient(R²) of 0.999. The percentage recovery ranged from 99.3% to 100.1% reflecting substantial accuracy. Precision assessments resulted %RSD values below 2.0, substantiating both repeatability and intermediate precision. Robustness evaluations involving minor alterations in wavelength exhibited negligible deviation, thereby affirming reliability. Additionally, forced degradation experiments substantiated the stability-indicating characteristics. The delineated UV-spectrophotometric technique is straightforward, analytically sensitive, and reproducible. It is eminently suitable for routine quality assessment and quantitative evaluation of Nirogacestat in bulk drug substances and tablet formulations.

🔖

Cite This Article

Ravisankar, P., Munnangi, M. E., Mandava, J., Dadı, V. (2026). Analytical Method Development and Validation for Nirogacestat Using UV Spectrophotometry. Hacettepe Üniversitesi Eczacılık Fakültesi Dergisi, Volume: 46 Issue: 3. https://doi.org/10.52794/hujpharm.1789440

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (20)

  1. Gounder M, Ratan R, Alcindor T, Schöffski P, Van Der Graaf WT, Wilky BA, et al. Nirogacestat, a γ-secretase inhibitor for desmoid tumors. N Engl J Med. 2023 9;388(10):898-912. https://doi.org/10.1056/nejmoa2210140
  2. Guo X, Li H, Lu X, Liu H, U K, Yan C, et al. Structural basis of human γ-secretase inhibition by anticancer clinical compounds. Nat Struct Mol Biol. 2025 32(4):719-28. https://doi.org/10.1038/s41594-024-01439-8
  3. Capaccione KM, Pine SR. The notch signaling pathway as a mediator of tumor survival. Carcinogenesis. 1;34(7):1420-30. https://doi.org/10.1093/carcin/bgt127
  4. Federman N. Molecular pathogenesis of desmoid tumor and the role of γ-secretase inhibition. NPJ Precis Oncol. 2022 6;6(1):62. https://doi.org/0.1038/s41698-022-00308-1
  5. Takahashi T, Prensner JR, Robson CD, Janeway KA, Weigel BJ. Safety and efficacy of gamma-secretase inhibitor Nirogacestat (pf-03084014) in desmoid tumor: Report of four pediatric/young adult cases. Pediatr Blood Cancer. 2020 67(10):e28636. https://doi.org/10.1002/pbc.28636
  6. Niessen J, Nilsson JM, Peters K, Indulkar A, Borchardt T, Koziolek M, et al. Development and validation of lc-ms/ms methods for the pharmacokinetic assessment of the protacs bavdeglutamide (arv-110) and vepdegestrant (arv-471). J Pharm Biomed Anal. 2024 15;249:116348. https://doi.org/10.1016/j.jpba.2024.116348
  7. Liu F, Sun C, Yang W, Yuan F, Gao Y. Structural characterization and functional evaluation of lactoferrin–polyphenol conjugates formed by free-radical graft copolymerization. Rsc Advances. 2015;5(20):15641-51. https://doi.org/10.1039/C4RA10802G
  8. Moosavi SM, Ghassabian S. Linearity of calibration curves for analytical methods: A review of criteria for assessment of method. Calibration and validation of analytical methods: A sampling of current approaches. 2018 25:109. https://doi.org/10.5772/intechopen.72932
  9. Shingote V, Mankar SD, Dighe SB. A review article on analytical methods development and validation. Res J Sci Technol. 2022;14(1):77-83. https://doi.org/10.52711/2349-2988.2022.00012
  10. Sankar PR, Divya M, Babu JC, Reshma SK. Development and validation of stability indicating hplc method for determination of Nirogacestat in bulk and pharmaceutical dosage form. Cuest Fisioter. 2025 20;54(4):1767-83. https://doi.org/10.48047/z2mej921
  11. Badgujar VM, Jain PS. Analytical method development and validation of an rp-hplc method for stability-indicating determination of idelalisib. Pharm Chem J. 2024: 58(7):1176-81. https://dx.doi.org/10.1007/s11094-024-03257-0
  12. Darwish HW, Bakheit AH, Al-Anazi ZS, Al-Shakliah NS, Al-Hossaini AM, Naguib IA, et al. Response surface methodology for optimization of micellar-enhanced spectrofluorimetric method for assay of foretinib in bulk powder and human urine. Spectrochim Acta A Mol Biomol Spectrosc. 2021 5;257:119811. https://doi.org/10.1016/j.saa.2021.119811
  13. Dadi V, Gandi A, Adari J, Sappa MK, Kollabathula VR. Quantification of Edoxaban Tosylate Monohydrate in Pharmaceutical API and Dosage Form by a Novel UV-Spectrophotmetric Method: Development and Validation. Hacettepe Univ J Fac Pharm. 2025;45(4):329-337. doi:10.52794/hujpharm.1649224.
  14. Shearer T, Comstock M, Williams Jr RL, Johnson MC, Cendrowicz E, Leonowens C, et al. Kinetics of Nirogacestat-mediated increases in b-cell maturation antigen on plasma cells inform therapeutic combinations in multiple myeloma. Cancer Res Commun. 2024 11;4(12):3114-23. https://doi.org/10.1158/2767-9764.CRC-24-0075
  15. KV UR, Neetu S. A quality by design-driven stability indicating uplc method for the development and validation of simultaneous Nirogacestat and impurity quantification. Res J Chem Environ. 2025;29:8. https://doi.org/10.25303/298rjce054065
  16. Koppisetty BR, Tatapudi HK, Dadi V, Gayathri PR, Komali P, Challa GN, et al. Qbd based rp-hplc method for simultaneous determination of a emtricitabine, tenofovir diproxil fumarate and efavirenz in tablet dosage form-an application to stability indicating assay. Anal Chem Lett. 2023 4;13(3):267-88. https://doi.org/10.1080/22297928.2023.2243279
  17. Panchumarthy R, Bathula S, Koppisetty BR, Dadi V. A stability indicating rp-hplc method for determination of foslevodopa and foscarbidopa in bulk and formulation. Sep Sci Plus. 2025;8(5):e70063. https://doi.org/10.1002/sscp.70063
  18. Dadi V, Annambhotla V, kumar Kallepalli A, Ponnam C, Gandi A. A novel rp-uplc technique for quantification of daunorubicin and cytarabine simultaneous in combined tablet dosage forms-its application in monitoring forced degradation studies. Curr Trends Biotechnol Pharm. 2025 10;19(2s):99-110. https://doi.org/10.5530/ctbp.2025.2s.10
  19. KV UR, Neetu S. A quality by design-driven stability indicating uplc method for the development and validation of simultaneous Nirogacestat and impurity quantification. Res J Chem Environ. 2025;29:8. https://doi.org/10.25303/298rjce054065
  20. Panchumarthy R, Bathula S, Koppisetty BR, Dadi V. A stability indicating rp-hplc method for determination of foslevodopa and foscarbidopa in bulk and formulation. Sep Sci Plus. 2025;8(5):e70063. https://doi.org/10.1002/sscp.70063